Olaf van Tellingen

Glioblastoma (GBM) is a highly aggressive brain tumor with a short overall survival of just 15 months. Tumor cells invade the normal surrounding brain and many drugs have little effect because these are unable to cross the blood-brain barrier (BBB). Our aim is to improve the treatment of GBM.

We try to identify (combinations of) drugs that target the vulnerabilities of these tumors and are able to cross the BBB in sufficient quantities to be efficacious. For this purpose, we use mouse models that closely recapitulate the human disease.